MARKET

GRTX

GRTX

GALERA THERAPEUTICS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.68
-0.11
-0.86%
After Hours: 12.68 0 0.00% 16:00 01/24 EST
OPEN
12.84
PREV CLOSE
12.79
HIGH
13.12
LOW
12.35
VOLUME
39.18K
TURNOVER
--
52 WEEK HIGH
19.50
52 WEEK LOW
8.16
MARKET CAP
308.91M
P/E (TTM)
-5.9690
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of GRTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

GRTX News

  • The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results
  • Benzinga.01/08 13:12
  • Galera Therapeutics Reports Dosing Of First Patient In Phase 2a Trial Of Avasopasem Manganese In Second Indication
  • Benzinga.01/07 21:40
  • Galera Therapeutics Announces Dosing of First Patient in Phase 2a Clinical Trial of Avasopasem Manganese (GC4419) in Second Indication
  • GlobeNewswire.01/07 21:40
  • CTIC, AKRX, QIWI and INPX among midday movers
  • Seeking Alpha - Article.12/18/2019 17:41

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About GRTX

Galera Therapeutics, Inc is a clinical stage biopharmaceutical company. It is focused on developing and commercializing a pipeline therapeutics to transform radiotherapy in cancer. It is focused on leveraging capability in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Its pipeline product are GC4419 and GC4711. Its lead product candidate GC4419, is a potent selective small molecule dismutase mimetic. The Company is initially focused on developing GC4419 for the reduction of severe oral mucositis (SOM). GC4419, is also known as avasopasem manganese, and has completed two clinical trials. The Company’s second dismutase mimetic product candidate is GC4711. The Company is specifically targeting GC4711, an analog of GC4419, to increase the anti-cancer efficacy of SBRT. It is in Phase 1 development both as a lyophilized product for intravenous administration given as an oral capsule.
More

Webull offers Galera Therapeutics Inc (GRTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.